Belhabri A, Heiblig M, Morisset S, Vila L, Santana C, Nicolas-Virelizier E
Cancer Med. 2023; 12(16):16929-16944.
PMID: 37548369
PMC: 10501294.
DOI: 10.1002/cam4.6322.
Martinez-Cuadron D, Megias-Vericat J, Gil C, Bernal T, Tormo M, Martinez-Sanchez P
Haematologica. 2023; 109(1):115-128.
PMID: 37199127
PMC: 10772508.
DOI: 10.3324/haematol.2022.282506.
Sbirkov Y, Schenk T, Kwok C, Stengel S, Brown R, Brown G
Front Cell Dev Biol. 2023; 11:1076458.
PMID: 37035245
PMC: 10076884.
DOI: 10.3389/fcell.2023.1076458.
Atsou K, Rachet B, Cornet E, Chretien M, Rossi C, Remontet L
Cancer Med. 2023; 12(7):8911-8923.
PMID: 36710405
PMC: 10134294.
DOI: 10.1002/cam4.5645.
Orvain C, Rodriguez-Arboli E, Othus M, Sandmaier B, Deeg H, Appelbaum F
Cancers (Basel). 2023; 15(2).
PMID: 36672303
PMC: 9856876.
DOI: 10.3390/cancers15020352.
Impact of treatment intensity on infectious complications in patients with acute myeloid leukemia.
Tober R, Schnetzke U, Fleischmann M, Yomade O, Schrenk K, Hammersen J
J Cancer Res Clin Oncol. 2022; 149(4):1569-1583.
PMID: 35583829
PMC: 10020242.
DOI: 10.1007/s00432-022-03995-2.
Healthcare Resource Utilization among Patients between 60-75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study.
Solana-Altabella A, Megias-Vericat J, Ballesta-Lopez O, Boluda B, Cano I, Acuna-Cruz E
Cancers (Basel). 2022; 14(8).
PMID: 35454828
PMC: 9032151.
DOI: 10.3390/cancers14081921.
Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study.
Martinez-Cuadron D, Megias-Vericat J, Serrano J, Martinez-Sanchez P, Rodriguez-Arboli E, Gil C
Blood Adv. 2021; 6(4):1278-1295.
PMID: 34794172
PMC: 8864639.
DOI: 10.1182/bloodadvances.2021005335.
Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia.
Fleischmann M, Schnetzke U, Frietsch J, Sayer H, Schrenk K, Hammersen J
J Cancer Res Clin Oncol. 2021; 148(6):1481-1492.
PMID: 34297206
PMC: 9114033.
DOI: 10.1007/s00432-021-03733-0.
Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial.
Heuser M, Smith B, Fiedler W, Sekeres M, Montesinos P, Leber B
Ann Hematol. 2021; 100(5):1181-1194.
PMID: 33740113
PMC: 8043884.
DOI: 10.1007/s00277-021-04465-4.
Descriptive and Functional Genomics in Acute Myeloid Leukemia (AML): Paving the Road for a Cure.
Pasquer H, Tostain M, Kaci N, Roux B, Benajiba L
Cancers (Basel). 2021; 13(4).
PMID: 33670178
PMC: 7916915.
DOI: 10.3390/cancers13040748.
Genetic and Genomic Landscape of Secondary and Therapy-Related Acute Myeloid Leukemia.
Higgins A, Shah M
Genes (Basel). 2020; 11(7).
PMID: 32640569
PMC: 7397259.
DOI: 10.3390/genes11070749.
Individualizing Treatment for Newly Diagnosed Acute Myeloid Leukemia.
Reville P, Kadia T
Curr Treat Options Oncol. 2020; 21(4):34.
PMID: 32318829
DOI: 10.1007/s11864-020-0710-x.
Treatment Strategies for Therapy-related Acute Myeloid Leukemia.
Dhakal P, Pyakuryal B, Pudasainee P, Rajasurya V, Gundabolu K, Bhatt V
Clin Lymphoma Myeloma Leuk. 2020; 20(3):147-155.
PMID: 31953046
PMC: 9302428.
DOI: 10.1016/j.clml.2019.12.007.
Myelodysplasia-related acute myeloid leukemia and acute promyelocytic leukemia: concomitant occurrence of two molecularly distinct diseases.
Vanegas Y, Azzouqa A, Menke D, Foran J, Vishnu P
Hematol Rep. 2018; 10(3):7658.
PMID: 30283621
PMC: 6151345.
DOI: 10.4081/hr.2018.7658.
Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP study.
Sengsayadeth S, Gatwood K, Boumendil A, Labopin M, Finke J, Ganser A
Blood Adv. 2018; 2(16):2127-2135.
PMID: 30143527
PMC: 6113606.
DOI: 10.1182/bloodadvances.2018019976.
Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis.
Boddu P, Kantarjian H, Garcia-Manero G, Ravandi F, Verstovsek S, Jabbour E
Blood Adv. 2018; 1(17):1312-1323.
PMID: 29296774
PMC: 5727976.
DOI: 10.1182/bloodadvances.2017008227.
Azacitidine or intensive chemotherapy for older patients with secondary or therapy-related acute myeloid leukemia.
Dumas P, Bertoli S, Berard E, Mediavilla C, Yon E, Tavitian S
Oncotarget. 2017; 8(45):79126-79136.
PMID: 29108292
PMC: 5668025.
DOI: 10.18632/oncotarget.15988.
Effect of the microtransplantation of allogeneic hematopoietic stem cells as maintenance therapy for elderly patients with acute leukemia.
Kong X, Chen Y, Wang L, Zhou Y, He Y, Nie W
Oncol Lett. 2015; 9(5):2331-2334.
PMID: 26137066
PMC: 4467360.
DOI: 10.3892/ol.2015.2995.
Comparable outcomes post allogeneic hematopoietic cell transplant for patients with de novo or secondary acute myeloid leukemia in first remission.
Michelis F, Atenafu E, Gupta V, Kim D, Kuruvilla J, Lipton J
Bone Marrow Transplant. 2015; 50(7):907-13.
PMID: 25822226
DOI: 10.1038/bmt.2015.59.